

Customer No. 25533

Confirmation No. 6734

IFW
DEC 07 2004
U.S. PATENT & TRADEMARK OFFICE
Customer No. 25533

PTO/SB/21 (03-03)

Approved for use through 04/30/2003. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMITTAL FORM

(to be used for all correspondence after initial filing)


Total Number of Pages in This Submission

Application Number	10/773,588
Filing Date	February 6, 2004
First Named Inventor	Louis Chupak, et al.
Art Unit	1614
Examiner Name	Not yet assigned
Attorney Docket Number	PC25656A

ENCLOSURES (Check all that apply)

<input type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Fee Attached <input type="checkbox"/> Amendment/Reply <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s) <input type="checkbox"/> Extension of Time Request <input type="checkbox"/> Express Abandonment Request <input checked="" type="checkbox"/> Information Disclosure Statement <input type="checkbox"/> Certified Copy of Priority Document(s) <input type="checkbox"/> Response to Missing Parts/ Incomplete Application <input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53	<input type="checkbox"/> Drawing(s) <input type="checkbox"/> Licensing-related Papers <input type="checkbox"/> Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation <input type="checkbox"/> Change of Correspondence Address <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Request for Refund <input type="checkbox"/> CD, Number of CD(s) _____	<input type="checkbox"/> After Allowance Communication to a Technology Center (TC) <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to TC (Appeal Notice, Brief, Reply Brief) <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input checked="" type="checkbox"/> Other Enclosure(s) (please Identify below): Statement as Provided by 34 CFR 1.97(b) Return Postcard
Remarks AUTORIZATION TO CHARGE THE FEE AND ANY ADDITIONAL FEES AS NECESSARY OR CREDIT ANY OVERPAYMENT TO DEPOSIT ACCOUNT 21-0718 IS HEREBY GIVEN.		

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Firm or Individual	J. Michael Dixon
Signature	
Date	11/30/04


CERTIFICATE OF TRANSMISSION/MAILING

I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O.Box 1450, Alexandria, VA 22313-1450 on this date 12-1-04

Typed or printed	Diane L. Hetzler	Date	12-1-04
Signature			

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



PC25656A

IN THE UNITED STATES PATENT & TRADEMARK OFFICE

Application No : 10/773,588
Applicant : Louis Chupak, et al
Filed : February 6, 2004
Title : Antibacterial Agents
TC/A.U. : 1614
Examiner : Not Yet Known
Docket No. : PC 25656A
Customer No. : 28880
Confirmation No : 6734

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Statement as Provided by 37 CFR 1.97(b)

Dear Sir:

The Applicants submit that a Supplemental Information Disclosure Statement submitted herewith is being filed within three months of the filing of a national application other than a continued prosecution application under 37 CFR 1.53(d); within three months of the date of entry of the national stage as set forth in 37 CFR 1.491 in an international application; before the mailing of the first Office Action on the merits, or before the mailing of a first Office Action after the filing of a request for continued examination under 37 CFR 1.114.

As such, the Applicants respectfully requests consideration of the enclosed Supplemental Information Disclosure Statement and request that all references cited herein be printed on the face of the patent upon grant of the Application.

Enclosed is the form PTO/SB/08A. Copies of all Foreign and Non Patent Literature Documents which are cited on the PTO/SB/08A form are enclosed, except for the U.S. Patent Documents, which are not required.

It is understood by the Applicants that this paper requires no fee; however, authorization is given to charge any necessary filing fees and any additional fees or credit any overpayment to Deposit Account 23-0455.

Dated: 11/30/04

Respectfully submitted,



J. Michael Dixon
Registration No. 32,410
Warner-Lambert Company
2800 Plymouth Road
Ann Arbor, MI 48105
Telephone: (734) 622-1705
Facsimile: (734) 622-1553

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet

1

of

8

Complete if Known

Application Number	10/773,588
Filing Date	FEBRUARY 5, 2004
First Named Inventor	L. Chupak et al
Art Unit	1614
Examiner Name	

Attorney Docket Number PC25656A

U. S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			
		US- 4,705,799	11-10-1987	Gregory	
		US- 5,043,443	08-27-1991	Carlson et al	
		US- 5,164,510	11-17-1992	Brickner	
		US- 5,182,403	01-26-1993	Brickner	
		US- 5,225,565	07-06-1993	Brickner	
		US- 5,231,188	07-27-1993	Brickner	
		US- 5,247,090	09-21-1993	Brickner	
		US- 5,529,998	06-25-1996	Habich et al	
		US- 5,547,950	08-20-1996	Hutchinson et al	
		US- 5,652,238	07-29-1997	Brickner et al	
		US- 5,684,023	11-04-1997	Riedl et al	
		US- 5,688,792	11-18-1997	Barbachyn et al	
		US- 5,698,574	12-16-1997	Riedl et al	
		US- 5,792,765	08-11-1998	Riedl et al	
		US- 5,827,857	10-27-1998	Riedl et al	
		US- 5,843,967	12-01-1998	Riedl et al	
		US- 5,861,413	01-19-1999	Habich et al	
		US- 5,869,659	02-09-1999	Stolle et al	
		US- 5,952,324	09-14-1999	Barbachyn et al	

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T ⁶
		Country Code ³ Number ⁴ Kind Code ⁵ (if known)				
		WO94/01110	01-20-1994	THE UPJOHN CO.		
		WO95/07271	03-16-1995	THE UPJOHN CO.		
		WO96/13502	05-09-1996	THE UPJOHN CO.		
		WO96/23788	08-08-1996	PHARMACIA		
		WO96/35691	11-14-1996	PHARMACIA		
		WO97/30995	08-28-1997	ZENECA		

Examiner Signature		Date Considered
--------------------	--	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				Complete if Known	
				Application Number	10/773,588
				Filing Date	February 5, 2004
				First Named Inventor	L. Chupak et al
				Art Unit	1614
				Examiner Name	
Sheet	2	of	8	Attorney Docket Number	PC25656A

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

U. S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			
		US- 5,990,136	11-23-1999	Barbachyn et al	
		US- 6,043,266	03-28-2000	Ennis et al	
		US- 6,069,145	05-30-2000	Betts	
		US- 6,069,160	05-30-2000	Stolle et al	
		US- 6,110,936	08-29-2000	Gravestock	
		US- 6,166,056	12-26-2000	Thomas et al	
		US- 6,194,441	02-27-2001	Roberts et al	
		US- 6,239,152	05-29-2001	Gordeev et al	
		US- 6,239,283	05-29-2001	Gage	
		US- 6,689,769	02-10-2004	Gordeev et al	
		US-			

FOREIGN PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)			T ⁶
		WO99/03846	01-28-1999	BAYER	
		WO99/29688	06-17-1999	PHARMACIA	
		WO99/37641	07-29-1999	BAYER AKTIEN...	
		WO99/37652	07-29-1999	BAYER AKTIEN...	
		WO99/64417	12-16-1999	ZENECA	
		WO00/21960	04-20-2000	ZENECA	

Examiner Signature		Date Considered
--------------------	--	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

<p>Substitute for form 1449/PTO</p> <p>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</p> <p><i>(Use as many sheets as necessary)</i></p>				<p>Complete if Known</p>	
				Application Number	10/773,588
				Filing Date	February 5, 2004
				First Named Inventor	L. Chupak et al
				Art Unit	1614
				Examiner Name	
Sheet	3	of	8	Attorney Docket Number	PC25656A

U. S. PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T ⁶
		Country Code ³ - Number ⁴ - Kind Code ⁵ (if known)				
		WO00/44741	08-03-2000	PHARMACIA		
		WO00/73301	12-07-2000	PHARMACIA		
		WO01/40236	06-07-2001	ASTRAZENECA AB		
		WO01/81350	11-01-2001	ASTRAZENECA		
		WO02/096916	12-05-2002	ASTRAZENECA AB		

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

¹EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ²Applicant's unique citation designation number (optional). ³See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet

4

af

8

Complete if Known

Complete it. Right now.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number			
Complete if Known			
Substitute for form 1449/PTO		Application Number	10/773,588
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>		Filing Date	February 5, 2004
		First Named Inventor	L. Chupak et al
		Art Unit	1614
		Examiner Name	
Sheet	4	of	8
		Attorney Docket Number	PC25656A

U. S. PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T
		Country Code ³ - Number ⁴ - Kind Code ⁵ (if known)				
		WO03/006440	01-23-2003	PHARMACIA		
		EP0417044A2	08-29-1990	CIBA-GEIGY AG		
		EP0697408B1	08-10-1995	MERCK PATENT		
		WO02/059116	08-01-2003	PHARMACIA &Upjohn		

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

***EXAMINER:** Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				Complete if Known	
				Application Number	10/773,588
				Filing Date	February 5, 2004
				First Named Inventor	L. Chupak et al
				Art Unit	1614
				Examiner Name	
Sheet	5	of	8	Attorney Docket Number	PC25656A

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.		
		ABDELAAL, et. al., "Synthesis of 1-[3-Methyl]-2(3H)-benzazolone-5- or 6-yl]-4-{4-[cis-2-(2,4-dichlorophenyl)-2-(1H-imidazol-1-yl-methyl)-1,3-dioxolan-4-yl]methylene oxyphenyl}piperazines" Journal of Heterocyclic Chem., 29, 1069, (1992).		
		BARBACHYN, et. al. "Identification of a Novel Oxazolidinone (U-100480) with Potent Antimycobacterial Activity." Journal of Medicinal Chemistry. 1996, 39, 680-685.		
		BLACHE, et. al. "Application of the Mercuric Acetate-Edetic Acid Oxidation Method To The Synthesis of 11-Aza-1,2,3,4,5,6,7,12bpOctahydroindolo[2,3-a]Quinolizines." Heterocycles, Vol. 45, No.1, Pp.57-69, 1997		
		BODOR, Nicholas and J. Hillis Miller, "Novel Approaches in Prodrug Design." Drugs of the Future Vol. VI, No. 3, 1981, pp. 165-182.		
		YAMAMOTO, Yutaka, and Akihiko Yanagi. "Studies on Organometallic Compounds, II Facile and Convenient Method for the Synthesis of Iodoazines through Iododestannation of Trimethylstannylazines." Chem Pharm. Bull. 30(5) 1731-1737(1982).		
		BRICKNER, et. al. "Synthesis and Antibacterial Activity of U-100592 and U-100766, Two Oxazolidinone Antibacterial Agents for the Potential Treatment of Multidrug-Resistant Gram-Positive Bacterial Infections." Journal of Medicinal Chemistry. 1996, 39, 673-679.		
		BUNDGAARD, Hans. "Design of prodrugs: Bioreversible derivatives for various functional groups and chemical entities." Design of Prodrugs, Chapter 1, 1985.		
		CAVA, Michael P. and Matthew I. Levinson. "Thionation Reactions of Lawesson's Reagents." Tetrahedron Vol. 41, No. 22, pp. 5061-5087, 1985.		
		CLARK, Robert L. and Arsenio A. Pessolano. "Synthesis of Some Substituted Benzoxazolones." Journal of the American Chemical Society." Vol. 80, pp. 1662, 1958.		
		COMINS, et. al. "Preparation of 2,6-Disubstituted 2,3-Dihydro-4-pyridones: Dehydrogenation of Trimethylsilyl Enol Ethers with Palladium (II) Acetate." Tetrahedron Letters, Vol. 36, No. 52, pp. 9449-9452, 1995.		

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet

6

of

8

		Complete if Known	
Application Number	10/773,588		
Filing Date	February 5, 2004		
First Named Inventor	L. Chupak et al		
Art Unit	1614		
Examiner Name			
Attorney Docket Number	PC25656A		

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		COMINS, et. al. "Regio- and Stereoselective Addition of Nucleophiles to 1-Phenoxy carbonyl-2,3-Dihydropyridinium Salts." <i>Heterocycles</i> , Vol. 37, No. 2, 1994, pgs 1121-1140.	
		DEHMLOW, Eckehard, and Ralf Westerheide. "Studies Towards 3,4-Dimethoxy-1-Methyl-1,2-Dihydropyridine, so-called Arecolidine, or its Tautomers." <i>Heterocycles</i> , Vol. 37, No. 1, 1994, pgs. 355-366.	
		DIEZ, et. al. "Preparation of a New Chiral 5,6-Dihydropyridinium Synthon." <i>Heterocycles</i> , Vol. 31, No. 3, 1990, pgs., 485-492.	
		DODD, Dharmpal and Allan Oehlschlager. "Efficient Route to the Synthesis of C-2, C-3 Substituted 4-Piperidones." <i>Tetrahedron Letters</i> , Vol. 32, No. 30, pp. 3643-3646, 1991.	
		EVANS, et. al. "Regioselective Preparation of a,B-Unsaturated Ketones via the Direct Dehydrogenation of Triisopropylsilyl Enol Ethers." <i>Tetrahedron Letters</i> , Vol. 36, No. 23, pp. 3985-3988, 1995.	
		GAGE, et. al. "Stereodivergent synthesis of sulfoxide-containing oxazolidinone antibiotics." <i>Tetrahedron Letters</i> , 41 (2000) 4301-4305.	
		GUERRY Philippe and Reinhard Neier, "Photochemical Cycloadditions to 5,6-Dihydro-4-pyridones." <i>Chimia</i> 41 (1987) No. 10 (October), pgs., 341-342.	
		GUERRY, Philippe and Reinhard Neier. "Reduktion von 4-Pyridinonen." <i>Synthesis</i> , June 1984 pp. 485-488.	
		HAIDER, et. al. "140. Synthesis of 4-Oxo-1,2,3,4-tetrahydropyridine (2,3-Dihydro-4(1H)pyridinone)." <i>Helvetica Chimica Acta</i> - Vol. 58, Fasc. 5 (1975) - Nr. 139 - 140 pp. 1287-1292.	
		HERRINTON, et. al. "Iodination and Metal Halogen Exchange of Aromatic Compounds: An Improved Preparation of a Key Oxazolidinone Antibiotic Intermediate." <i>Organic Process Research and Development</i> 2001, 5, 80-83.	

Examiner Signature	Date Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.
This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:
Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Application Number	10/773,588
Sheet	7	of	8	Filing Date	February 5, 2004
				First Named Inventor	L. Chupak et al
				Art Unit	1614
				Examiner Name	
				Attorney Docket Number	PC25656A

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		ISHII, et. al. "Rhodium-Catalyzed Reaction of N-Acylpiperazines with CO and Ethylene, Carbonylation at a C-H Bond Directed by an Amido Group." Tetrahedron Letters, Vol. 38, No. 43, pp. 7565-7568, 1997.	
		KIRSCHBAUM, Stephen, and Herbert Waldmann. "Construction of the Tricyclic Benzoquinolizine Ring System by Combination of a Tandem Mannich-Michael Reaction with a Heck Reaction." Tetrahedron Letters, Vol. 38, No. 16, pp. 2829-2832, 1997.	
		KIRSCHBAUM, Stepen, and Herbert waldmann. "Three-Step Acces to the Tricyclic Benzo[a]quinolizine Ring System." Journal of Organic Chemistry. 1998, 63, 4936-4946.	
		LOCK, Ralf, and Herbert Waldmann. "Asymetric Synthesis of Highly Functionalized Tetracyclic Indole Bases Embodying the Basic Skeleton of Yohimbinep and Reserpine Type Alkaloids." Tetrahedron Letters, vol. 37, No. 16, pp. 2753-2756, 1996.	
		LOCK, Ralf, and Herbert Waldmann. "Enantioselective Construction of Highly Fuctionalized Indoloquinolizines Congeners to Polycyclic Indole Alkaloids." Chem. Eur. J. 1997, 3, No. 1, pp. 143-151.	
		MAI, et. al. "N-[4-(1,1'-Biphenyl)Methyl]-4-(4-Thiomorpholinylmethyl) Benzenamines, a New Class of Synthetic Antituberculosis Agents Active Against Mycobacterium Avium." Medicinal Chemistry Research, 9:3 (1999) 149-161.	
		NOTARI, Robert E., "Theory and Practice of Prodrug Kinetics." Methods in Enzymology, Vol. 112, 1985, pp. 309-323.	
		REGGELIN, Michael, and Cornelia Zur, "Sulfoximines; Structures, Properties and Synthetic Applications." Synthesis, 2000, No. 1, 1-64.	
		ROUSH, William R., and Bradley B. Brown. "Enantioselective Syntehsis of 2-Alkyl-5-methylene-1,3-dioxolan-4-ones and Exo-Selective Diels-Alder Reactions with Cyclopentadiene." Journal of Organic Chemistry. 1992, 57, 3380-3387.	
		STUTZ, P, and PA Stadler, "A Novel Approach to Cyclic b-Carbonyl-Enamines 7,8 - Lysergic Acid Derivatives Via The Polonovski Reaction." Tetrahedron Letters No. 51, pp. 5095 - 5098, 1973.	

Examiner Signature	Date Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.
This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:
Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				Complete if Known	
				Application Number	10/773,588
				Filing Date	February 5, 2004
				First Named Inventor	L. Chupaket al
				Art Unit	1614
				Examiner Name	
Sheet	8	of	8	Attorney Docket Number	PC25656A

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			²
		WALDMANN et. al. "Asymmetric Synthesis of Indolo[2,3-a]quinolizidin-2-onesCongeners to Yohimbine-Type Alkaloids." Tetrahedron Vol. 49, No. 2, 1993, Pp. 397-416.			
		English Abstract for GUERRY, Philippe "Reduktion von 4-Pyridinonen"			
		English Abstract for EP0417044A2			
		English Abstract for EP0697408B1			

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.